10x Genomics, Inc. - Common Stock - Nakit Akışı (NASDAQ:TXG)

Financials

İşletme faaliyetlerinden elde edilen nakit -217.9 M-21.37 M-33.61 M-15.2 M6.66 M136.05 M 127.82 M Yatırım faaliyetlerinden elde edilen nakit -38.39 M-106.73 M-350.89 M133.49 M-32.63 M-13.44 M -12.86 M Finansman faaliyetlerinden elde edilen nakit 468.91 M35.3 M15.82 M13.67 M10.91 M6.8 M -2.04 M Serbest nakit akışı -217.9 M-21.37 M-33.61 M-15.2 M6.66 M130.12 M 122.18 M

10x Genomics, Inc. - Common Stock

10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics.

TXG

Financials

10x Genomics, Inc. - Common Stock

Haberler

10x Genomics hissesi 26,56 dolarda 52 haftalık zirve yaptı

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates

Cathie Wood’un ARK’ı AMD hissesi sattı, Shopify ve GeneDx aldı

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?

Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?

Labcorp Gears Up to Report Q1 Earnings: What's in Store?